| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 18, 2019 | SVP Global Operations and R&D | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 736 | $15.57 | 16,422 | |
| Oct 25, 2019 | Director, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 15,000 | $14.19 | 260,418 | |
| Oct 16, 2019 | SVP and GM of Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,452 | -- | 6,452 | |
| Oct 16, 2019 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,195 | -- | 6,195 | |
| Oct 16, 2019 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,139 | -- | 50,139 | |
| Oct 16, 2019 | EVP and CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,320 | -- | 15,320 | |
| Oct 16, 2019 | SVP Global Operations and R&D | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,945 | -- | 6,945 | |
| Oct 16, 2019 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,357 | -- | 8,357 | |
| Aug 18, 2019 | EVP and CFO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 826 | $19.10 | 33,438 | |
| Aug 06, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,650 | $10.68 | 72,669 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.